Novel Target for Pharmacological Treatment of Epilepsy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 184
Special Issue Editor
Interests: epilepsy; status epilepticus; MRI; EEG
Special Issue Information
Dear Colleagues,
Epilepsy, a neurological condition, impacts approximately 65 million individuals across the globe. Roughly 30% of epilepsy patients do not respond well to antiseizure (antiepileptic) medications, leading to the significant therapeutic challenge of managing pharmacoresistant epilepsy. Consequently, there is an urgent need for the development of more effective epilepsy treatments in order to increase the proportion of patients experiencing life without seizures. Existing antiseizure drugs target known molecular mechanisms, but the discovery of novel targets and their corresponding ligands holds promise for developing innovative medications, with additional mechanisms of action targeting pharmacoresistant epilepsy.
In addition, antiseizure drugs typically do not address epileptogenesis triggered by initial insults such as prolonged seizures or status epilepticus, cortical injury, or stroke. The enduring process of epileptogenesis has been shown to transform a normal brain into an epileptic brain exhibiting hypersynchronous excitability. It is conceivable that halting or slowing the progress of epileptogenesis could prevent the development of epilepsy. Ideally, anti-epileptogenic drugs would be most effective prior to the onset of seizure activity, necessitating the identification of biomarkers markers for epileptogenesis.
Given the above considerations, this Special Issue, entitled “Novel Targets for Pharmacological Treatment of Epilepsy,” welcomes research on the discovery of new molecules demonstrating antiepileptic and antiepileptogenic effects. This Issue will also place particular emphasis on potential targets to enable the treatment of benzodiazepine-resistant prolonged seizures. Authors are encourages to submit original research articles and comprehensive reviews based on in vitro experiments, animal models of seizures with a focus on antiepileptic and antiepileptogenesis molecules, and clinical studies.
Dr. Tanveer Singh
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epilepsy
- antiepileptic drugs
- status epilepticus
- novel therapy
